Oral anticoagulants Sao Paulo
-
Upload
antonio-raviele -
Category
Health & Medicine
-
view
132 -
download
2
Transcript of Oral anticoagulants Sao Paulo
![Page 1: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/1.jpg)
Oral AnticoagulantsOral Anticoagulants
Antonio Raviele, MD, FESC, FHRS Antonio Raviele, MD, FESC, FHRS
SOBRAC 2015, Sao Paulo - Brazil, 4-6 November 2015 SOBRAC 2015, Sao Paulo - Brazil, 4-6 November 2015
ALFA – Alliance to Fight Atrial fibrillation, Mestre – Venice, ItalyALFA – Alliance to Fight Atrial fibrillation, Mestre – Venice, Italy
![Page 2: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/2.jpg)
• Rationale for the use of OACs in AF pts• Different types of OACs• Clinical results for the prevention of TE • Net clinical benefit of the different OACs• Indications to antithrombotic treatment• Which OAC to start?• Which NOAC to prefer?
Main IssuesMain Issues
![Page 3: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/3.jpg)
Ischemic Areas
Cerebral embolism as complication of AF
![Page 4: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/4.jpg)
AF 4,5%AF 4,5%
Controls 0,2% - 1,4%Controls 0,2% - 1,4%
Annual Incidence in pts with AFAnnual Incidence in pts with AF
AF & Stroke
(The SPAF Investigators. AIM 1992; 116: 1 – 5)(The SPAF Investigators. AIM 1992; 116: 1 – 5)
![Page 5: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/5.jpg)
Strokes related to Afib are more severe
The European Community Stroke Project
Lamassa M et al. Stroke (2001) 32: 392-398
Multi-centre, multi-national hospital-based registry involving 4462 patients hospitalized for first stroke
AFib diagnosed in 803 stroke patients (18%)
At 3 months, 32.8% of stroke patients with AFib were dead vs 19.9% of stroke patients without AFib
AFib increased by approximately 50% the probability of remaining disabled
![Page 6: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/6.jpg)
AFib is Associated with Progressive Risk of StrokeAFib is Associated with Progressive Risk of Stroke• Independent predictor of stroke recurrence and severityIndependent predictor of stroke recurrence and severity
Simons, LA et al. Stroke (1998) 29: 1341
Cum
ulat
ive
haza
rd o
f fat
al s
trok
e
1000
0.01
0.02
0.04
0.050.05
0.03
9080706050403020100
Months of follow-up
AF Present
AF Absent
![Page 7: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/7.jpg)
• To teduce the risk of thromboembolic events
when this risk outweighs the risk of bleeding
associated with the use of OACs.
Rationale for OACs in AFRationale for OACs in AF
![Page 8: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/8.jpg)
• Rationale for the use of OACs in AF pts• Different types of OACs• Clinical results for the prevention of TE • Net clinical benefit of the different OACs• Indications to antithrombotic treatment• Which OAC to start?• Which NOAC to prefer?
Main IssuesMain Issues
![Page 9: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/9.jpg)
• Vitamin K Antagonists (VKA)
• No Vitamin K Antagonists OACs (NOACs) or
Direct OACs (DOACs)
Different types of OACsDifferent types of OACs
![Page 10: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/10.jpg)
• Vitamin K Antagonists, such as warfarin, are the
traditional OACs and until 2009 have been the only
class of OACs available.
Vitamin K AntagonistsVitamin K Antagonists
![Page 11: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/11.jpg)
Point of action of VKA in the coagulation cascade.
Steffel J , Braunwald E Eur Heart J 2011;32:1968-1976
![Page 12: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/12.jpg)
• The Non-VKA OACs (NOACs) or Direct OACs
(DOACs) are new compounds developed in the recent
years.
NOACs or DOACsNOACs or DOACs
![Page 13: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/13.jpg)
Point of action of novel oral anticoagulants in the coagulation cascade.
Steffel J , Braunwald E Eur Heart J 2011;32:1968-1976
![Page 14: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/14.jpg)
• Rationale for the use of OACs in AF pts• Different types of OACs• Clinical results for the prevention of TE • Net clinical benefit of the different OACs• Indications to antithrombotic treatment• Which OAC to start?• Which NOAC to prefer?
Main IssuesMain Issues
![Page 15: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/15.jpg)
Hart RG, et al. Ann Intern Med. 2007; 146: 857-867
- 64%
Adjusted-Dose Warfarin Compared with Placebo or No Treatment*
------
![Page 16: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/16.jpg)
Hart RG, et al. Ann Intern Med. 2007; 146: 857-867
Safety Outcomes for Major Antithrombotic Comparisons*
![Page 17: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/17.jpg)
Limitations of VKA therapyLimitations of VKA therapy
Ansell J, et al. Chest 2008;133;160S-198S. Umer Ushman MH, et al. J Interv Card Electrophysiol 2008;22:129-137.Nutescu EA, et al. Cardiol Clin 2008;26:169-187.
![Page 18: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/18.jpg)
This explains
• the low use and the high discontinuation
rate of warfarin in the real world,
• the inadequate level of anticoagulation
reached in many patients
Underuse of warfarinUnderuse of warfarin
![Page 19: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/19.jpg)
Management of AF in clinical practice: Management of AF in clinical practice: VKA prescriptionVKA prescription
N=11.409ATRIA Cohort, USA
Go AS, et al.JAMA 2003;290:2685
N=5.333EuroHeart SurveyNieuwlaat R, et al.
Eur Heart J 2005;26:2422
N=23.657Medicare Cohort, USABirman-Deych E, et al.Stroke 2006;37:1070
No OACs VKA
55%67%64% 55%67%64%
![Page 20: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/20.jpg)
Mean % of Time spent in Therapeutic Range (TTR): INR 2.0-3.0
Hallgreen CE et al. Pharmacoepidemiol Drug Saf. 2014; ;23: :974-83
![Page 21: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/21.jpg)
Wallentin L et al. The Lancet 2010; 376, 975-983
Mean % of TTR in RE-LYCountry- based variation in average TTR
![Page 22: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/22.jpg)
Verheugt FWA et al. The Lancet 2015; 386, 303-310
The 4 large RCTs comparing NOACs with warfarin for stroke prevention in AF (71.683 pts)
![Page 23: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/23.jpg)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a
meta-analysis of randomised trials
Christian T Ruff, Robert P Giugliano, Eugene Braunwald, Elaine B Hoffman, Naveen Deenadayalu, Michael D Ezekowitz, A John Camm, Jeffrey I Weitz, Basil S Lewis, Alexander
Parkhomenko, Takeshi Yamashita, Elliott M Antman.
The Lancet 2014; 383: 955-962
![Page 24: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/24.jpg)
Ruff CT et al. The Lancet 2014; 383: 955-962
Stroke or Systemic Embolic Events
![Page 25: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/25.jpg)
Secondary efficacy and safety outcomes
Ruff CT et al. The Lancet 2014; 383: 955-962
![Page 26: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/26.jpg)
Advantages of therapy with NOACsAdvantages of therapy with NOACs
Ruff CT et al. The Lancet 2014; 383: 955-962
![Page 27: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/27.jpg)
Ansell J Circulation 2012;125:165-170
![Page 28: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/28.jpg)
• Rationale for the use of OACs in AF pts• Different types of OACs• Clinical results for the prevention of TE • Net clinical benefit of the different OACs• Indications to antithrombotic treatment• Which OAC to start?• Which NOAC to prefer?
Main IssuesMain Issues
![Page 29: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/29.jpg)
Should this patient be treated with OACsShould this patient be treated with OACs
??
Critical questionCritical question
![Page 30: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/30.jpg)
OAC / Net Clinical BenefitOAC / Net Clinical Benefit
Potential benefit of ischemic
stroke prevention
Potential risk of serious
bleeding, in particular ICH
![Page 31: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/31.jpg)
OAC / Net Clinical BenefitOAC / Net Clinical Benefit
(Isoff OAC – Ison OAC) – 1.5 x (ICHon OAC –ICHon OAC)
number of IS avoided by OACs - number of ICH attributable to OACs x 1.5 number of IS avoided by OACs - number of ICH attributable to OACs x 1.5
to account for the generally more disastrous effects of an intracranial bleed compared with an ischemic stroke
Friberg L, et al. Circulation 2012; 125: 2298-2307
![Page 32: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/32.jpg)
Circulation 2012; 125: 2298-2307
Thromb Haemost 2011; 106: 739-749
Thromb Haemost 2012; 107: 584-589
Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex).Lip GY, Skjøth F, Rasmussen LH, Nielsen PB, Larsen TB.
J Am Coll Cardiol. 2015 ; 66: 488-90.
![Page 33: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/33.jpg)
Olesen JB et al. Thromb Haemost 2011; 106: 739-749
![Page 34: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/34.jpg)
Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex)
Lip GYH et al. J Am Coll Cardiol. 2015; 66: 488-490.
![Page 35: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/35.jpg)
Banerjie A et al. Thromb Haemost 2012; 107: 584-589
![Page 36: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/36.jpg)
Stroke rate per yearStroke rate per year
Threshold for starting OAC therapyThreshold for starting OAC therapy
taking into account that NOACs reduce by 50% the
annual incidence of ICH compared to warfarin
Warfarin: 1.7%Warfarin: 1.7%NOACs: 0.9% NOACs: 0.9%
![Page 37: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/37.jpg)
• Rationale for the use of OACs in AF pts• Different types of OACs• Clinical results for the prevention of TE • Net clinical benefit of the different OACs• Indications to antithrombotic treatment• Which OAC to start?• Which NOAC to prefer?
Main IssuesMain Issues
![Page 38: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/38.jpg)
Lip GYH, Lane DA. JAMA 2015; 313:1950-1962
Algorithm for Risk Stratification and Selection of Anticoagulation Therapy for Stroke Prevention in AF
![Page 39: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/39.jpg)
• Rationale for the use of OACs in AF pts• Different types of OACs• Clinical results for the prevention of TE • Net clinical benefit of the different OACs• Indications to antithrombotic treatment• Which OAC to start?• Which NOAC to prefer?
Main IssuesMain Issues
![Page 40: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/40.jpg)
Figure 1. Percent of patients free from stroke over time, stratified by time spent in therapeutic range (INR 2.0–3.0).
FD Richard Hobbs et al. European Journal of Preventive Cardiology 2015;2047487315571890
![Page 41: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/41.jpg)
Lip GYH, Lane DA. JAMA 2015; 313:1950-1962
![Page 42: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/42.jpg)
Lip GYH, Lane DA. JAMA 2015; 313:1950-1962
Algorithm for Risk Stratification and Selection of Anticoagulation Therapy for Stroke Prevention in AF
![Page 43: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/43.jpg)
• Rationale for the use of OACs in AF pts• Different types of OACs• Clinical results for the prevention of TE • Net clinical benefit of the different OACs• Indications to antithrombotic treatment• Which OAC to start?• Which NOAC to prefer?
Main IssuesMain Issues
![Page 44: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/44.jpg)
Choice of the NOAC
No head-to-head comparisons exist between the different NOACs
So it is difficult to provide definitive recommendations on which
NOAC should be used in the single patient.
Indeed, NOACs are all individually noninferior to warfarin in terms
of efficacy for stroke prevention in patients with AF
However, some patient and drug characteristics may help in
decision making
![Page 45: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/45.jpg)
Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation
Shields AM, Lip GYH. Journal of Internal Medicine 2015; 278,:1-18
![Page 46: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/46.jpg)
Conclusions (1)
• VKA are very effective drugs in preventing TEE in pts with AF.
• NOACs are at least as effective (if not more effective) than VKA,
and associated with significantly lower risk of serious bleeding, i.e
intracranial hemorrhages.
• The favorable net clinical benefit of the different OACs prompts
their use in the majority of pts with AF, with the only exception of
those at low risk of stroke, i.e males with CHA2DS2-VASc score = 0
and females with CHA2DS2-VASc score = 1.
![Page 47: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/47.jpg)
Conclusions (2)
• The SAME-TT2R2 score system may be used to decide which OAC
(warfarin or NOACs) to start in newly diagnosed non anticoagulated
pts.
• Although no head-to-head comparisons exist between the different
NOACs, some patient and drug characteristics may help in selecting
which drug to use in single patients.
![Page 48: Oral anticoagulants Sao Paulo](https://reader037.fdocuments.us/reader037/viewer/2022103010/58f02aad1a28ab427d8b4613/html5/thumbnails/48.jpg)